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In stressed cells, apoptosis ensues when Bcl-2
family members Bax or Bak oligomerize and permea-
bilize the mitochondrial outer membrane. Certain
BH3-only relatives can directly activate them to
mediate this pivotal, poorly understood step. To
clarify the conformational changes that induce Bax
oligomerization, we determined crystal structures
of BaxDC21 treated with detergents and BH3
peptides. The peptides bound the Bax canonical
surface groove but, unlike their complexes with pro-
survival relatives, dissociated Bax into two domains.
The structures define the sequence signature of acti-
vator BH3 domains and reveal how they can activate
Bax via its groove by favoring release of its BH3
domain. Furthermore, Bax helices a2–a5 alone adop-
ted a symmetric homodimer structure, supporting
the proposal that two Bax molecules insert their
BH3 domain into each other’s surface groove to
nucleate oligomerization. A planar lipophilic surface
on this homodimer may engage the membrane. Our
results thus define critical Bax transitions toward
apoptosis.
INTRODUCTION
In response to most kinds of stress, the tripartite Bcl-2 family of
proteins governs commitment of cells to apoptosis (Youle and
Strasser, 2008). The death warrant is conveyed by distant
cousins of Bcl-2, termed BH3-only proteins because they share
with the family only the third of the four Bcl-2 Homology (BH)
domains. They use the BH3 domain, an amphipathic a helix, to
engage and neutralize their prosurvival relatives and probably
also to activate the critical effectors Bax and Bak, which seal
the cell’s fate by oligomerizing on the mitochondrial outer
membrane (MOM) and provoking its permeabilization (Weiet al., 2001). The resulting release of cytochrome c and other pro-
apoptotic proteins initiates a proteolytic cascade that ensures
the cell’s demise.
In healthy cells, Bax is largely cytosolic, but it translocates to
the MOM when cells receive an apoptotic stimulus (Edlich
et al., 2011; Wolter et al., 1997). Like the prosurvival Bcl-2 pro-
teins (Muchmore et al., 1996), cytosolic Bax comprises a globular
bundle of nine a helices (Suzuki et al., 2000). The last helix (a9)
may regulate Bax activity, as it either anchors Bax in the MOM
or resides in a hydrophobic groove on the surface of cytosolic
Bax (Suzuki et al., 2000). The homologous groove on the prosur-
vival proteins, comprising mainly a2 through a5, is the canonical
binding site for BH3 domains from both BH3-only proteins and
Bax or Bak (Czabotar et al., 2011; Sattler et al., 1997).
Defining how Bax metamorphoses from an inert cytosolic
monomer into the cytotoxic MOM-perforating oligomer has
been deemed the ‘‘holy grail’’ of apoptosis research (Youle and
Strasser, 2008). This pivotal step remains poorly understood,
largely because no structure of any activated form of Bax (or
Bak) has been available. Biochemical studies, however, have
provided insights. First, certain nonionic detergents induce
many of its conformational changes, including exposure of an
N-terminal epitope, translocation to the MOM, and oligomeriza-
tion (Hsu et al., 1997; Hsu and Youle, 1997). Also, studies with
BH3 peptides, or full-length BH3-only proteins, in mitochondrial
or liposomal systems suggest that certain BH3-only proteins
termed ‘‘activators,’’ notably Bid and Bim, can bind transiently
to Bax and induce its activation, whereas the others, termed
‘‘sensitizers’’ (e.g., Bad), act instead by freeing the activators
or Bax from prosurvival relatives (Certo et al., 2006; Kim et al.,
2006; Kuwana et al., 2002, 2005; Letai, 2009; Llambi et al.,
2011). The sequence characteristics distinguishing activators
from sensitizers are unknown. Some experiments suggest that
an activator BH3 domain binds transiently to a ‘‘rear pocket’’
on Bax, distal to its canonical surface groove (Gavathiotis
et al., 2008, 2010; Kim et al., 2009), but how this interaction
would displace a9 from the canonical site and lead to Bax oligo-
merization remains unclear. Recent biochemical studies suggest
that certain BH3 domains instead activate the constitutivelyCell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc. 519
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Figure 1. Dimerization of BaxDC21 Promoted by Octylmaltoside or
BH3 Peptides
(A) Gel filtration profile of BaxDC21 treated with CHAPS, BimBH3, octylmal-
toside (OM), or CHAPS and BimBH3.
(B) Blue native PAGE of BaxDC21 showing dimerization with OM or with
CHAPS plus BimBH3 peptide. The Bim-induced dimer probably is more
diffuse than the OM one because the peptide partially disassociates during the
run. The faster migrating monomer produced by BimBH3 alone may be
indicative of an altered monomer conformation.
(C) Blue native PAGE of BaxDC21, showing dimers in the presence of CHAPS
and certain BH3 peptides, but not Noxa or Bad.
520 Cell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc.MOM-associated Bak by binding to its canonical surface groove
(Dai et al., 2011).
Homo-oligomerization of Bax requires its BH3 domain (the
a2 helix) (Wang et al., 1998). Deletion of Bax segments suggests
that its a2–a5 helices alone can oligomerize and that this
core, together with a9, suffices for MOM permeabilization
(George et al., 2007). Recent crosslinking studies suggest that
the homo-oligomerization of both Bax and Bak starts when the
BH3 domain of one monomer is exposed and engages the
canonical binding groove (mainly a3–a5) of another activated
monomer, forming ‘‘BH3-in-groove’’ dimers that multimerize by
a separate interface (Bleicken et al., 2010; Dewson et al., 2008,
2009, 2012; Oh et al., 2010; Zhang et al., 2010). Other models
of the oligomerization have also been suggested (Bogner et al.,
2010; Pang et al., 2012; Westphal et al., 2011).
Here, we describe crystal structures that clarify the structural
transitions of Bax. Because the hydrophobic a9 helix can
compromise such studies by causing aggregation, we have
primarily studied the C-terminally truncated BaxDC21, which
we consider a surrogate for Bax tail-anchored in the MOM.
With this construct, we have obtained atomic structures of Bax
in complex with BH3 peptides. They provide insights regarding
Bax activation and the nature of activator BH3 domains. Extend-
ing those insights, we also describe a crystal structure of the Bax
domain containing only helices a2 through a5. Significantly, the
structure reveals a symmetric homodimer closely akin to that
proposed to nucleate Bax and Bak oligomerization (Dewson
et al., 2008). The findings not only define important transitions
in Bax on the path to apoptosis but also provide a structural
basis for eventually manipulating Bax activity pharmacologically.
RESULTS
Dimerization of BaxDC21
Treatment of BaxDC21 with the nonionic detergent octylmalto-
side produced primarily a dimer, as assessed by gel filtration
and blue native PAGE (Figures 1A and 1B). Alone, the detergent
CHAPS, which does not itself affect the Bax structure (Hsu and
Youle, 1998), did not induce dimers, but CHAPS plus certain
BH3 peptides, namely those from Bim, Bid, Bax, and Bak, but
not those from Bad or Noxa, readily dimerized BaxDC21 (Fig-
ure 1C). The responses of BaxDC21 to detergents resemble
those of full-length Bax in cell lysates (Hsu and Youle, 1997,
1998), and the observed specificity of the BH3 peptides is
consistent with peptide-induced activation of the full-length
protein (Letai et al., 2002), suggesting that this construct is rele-
vant to the behavior of the native protein and that the assay
reflects Bax activation. Furthermore, the N-terminal epitope for
antibody 49F9 (Figure 1D and Figure S1 available online), which
only recognizes Bax in etoposide-treated cells (Figure S1B), was
exposed in BaxDC21 during treatment with octylmaltoside and(D) SDS PAGE showing exposure of the N-terminal epitope 49F9 by immu-
noprecipitation of BaxDC21 during treatment with octylmaltoside. As noted
later, the epitope is exposed only transiently during the transition from
monomer to dimer (Figure 5). Asterisk indicates immunoglobulin light chain.
Data are representative of three experiments.
See also Figure S1.
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Figure 2. Structure of BidBH3:BaxDC21 Complex
(A) Dimer of BaxDC21, colored rainbow (blue N terminus to red C terminus) in
complex with BidBH3 (magenta), illustrating domain swapping of helices 6–8
(colored orange and red) across the dotted line.
(B) BidBH3 peptide (magenta) projects four canonical hydrophobic residues
(h1 through h4) into the canonical binding groove of Bax (green). The h0
residues I82 and I83make additional interactions with the Bax groove. Bid D95
forms a salt link to Bax R109 (cyan). Other Bax side-chains shown (cyan) are
R94 (close to Bid I83) and I66 and Y164 (both close to Bid M97).
See also Figure S2.modestly by BimBH3 plus CHAPS (Figure S1C), just as other
nonionic detergents expose the related 6A7 epitope in full-length
Bax (Hsu and Youle, 1997).
BH3 Peptides Bind BaxDC21 in Its Groove
Purified Bax dimer induced by the BidBH3 peptide and CHAPS
(as in Figure 1A) was reconstituted with a 2-fold molar excess
of the peptide and crystallized. The structure (Table S1 and Fig-
ure 2A) reveals a domain-swapped dimer topologically identical
to that reported for Bcl-xLDC exposed to high pH (O’Neill et al.,
2006). As is evident with that Bcl-xLDC dimer, we conclude that
the globular Bax structure, comprising helices a1–a5 from one
polypeptide and helices a6–a8 from the other (region above
dotted line in Figure 2A), represents the structure of the BaxDC21
monomer, except for the altered conformation at the a5–a6
corner. We address the significance of this domain-swapped
dimer later.
Notably, the BidBH3 peptide occupies the canonical surface
groove (Figure 2B) rather than the proposed BH3 peptide-
binding site on Bax (Gavathiotis et al., 2008) (see Discussion).
The association resembles that of BH3 peptides engaging pro-
survival relatives. The peptide is a-helical (Figures S2A and
S2B) from its N terminus (S76) to M97 but is loosely ordered
thereafter. It interacts with Bax by inserting the four signature
BH3 hydrophobic residues, h1 through h4 (Bid I86, L90, V93,
and M97), into the hydrophobic groove. These contacts, and
the salt bridge between Bid D95 and Bax R109 in a5, mirror
those of BH3 peptides with prosurvival proteins (Sattler et al.,
1997) (see also Figure S2B). Notably, we observed additional
hydrophobic interactions between residues near the N terminus
of the Bid peptide (I82/I83), designated ‘‘h0,’’ with the Bax a3 and
a4 helices (Figure 2B). No significant interactions appeared
C-terminal to Bid M97 (h4).
We similarly crystallizedBaxDC21 in complexwith theBaxBH3
peptide and determined its structure (Table S1 and Figures S2B–
S2E), which closely resembles that of the BidBH3 complex.
Again, the peptide is loosely ordered beyond the h4 residue
(L70). This complex is relevant to Bax oligomerization because
three independent lines of evidence suggest that it mimics the
Bax structure formed during apoptosis. First, in the Bax oligomer
formed by an apoptotic stimulus, Bax BH3 residue T56 comes
close enough to Bax R94 in the groove to allow efficient disulfide
linkage of T56C to R94C (Dewson et al., 2012), in accord with the
short distance between their Cb atoms (4.9 A˚) in the BaxBH3:
BaxDC21 complex (Figure S2D). Second, electron paramagnetic
resonance (EPR) studies on activated Bax in liposomes (Bleicken
et al., 2010) place the twoC62 residues within a dimer 24 A˚ apart,
similar to the 21.5 A˚ in the BaxBH3:Bax structure (Figure S2E).
Finally, site-specific photocrosslinking also places the Bax BH3
region in the interface of a symmetric Bax homodimer (Zhang
et al., 2010). These results are in full accord with the BH3-in-
groove homodimeric structure described below.
Sequence Signature of Activator BH3 Domains
To identify specific BH3 residues that convey activator function,
we tested structure-guided mutant peptides (Figure 3A) for
capacity to bind to BaxDC21 and dimerize it, as well as to induce
full-length Bax to permeabilize liposomes and mitochondriaCell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc. 521
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Figure 3. Characteristics of Activator BH3 Domains
(A) BH3 peptide sequences.
(B) Blue native PAGE assays of CHAPS/peptide-induced dimerization of BaxDC21.
(C) Release of fluorescent dextran from liposomes exposed to full-length Bax and BH3 peptides. Note especially loss of function in Bid I82A/I83A and gain of
function in Noxa C25I and Bad mut4/mini. Error bars represent SEM of at least three independent experiments.
(D) Noxa mutant C25I and Bad mut4/mini, but not wild-type peptides nor NoxaC25I with Ala at h0, release cytochrome c from mouse liver mitochondria derived
from Bak/mice and reconstituted with recombinant wild-type, full-length Bax. SN, supernatant. See also Table S2. (Badmut4 was not included in liposomes or
MLM experiments as it permeabilized these in the absence of Bax.)
(E) The Bax groove mutant R109D is not dimerized by CHAPS with wild-type BaxBH3 peptide but, rather, is with the Bax peptide D68R, which cannot dimerize
wild-type Bax. Data are representative of three experiments.
See also Figure S3.
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BBimBH3:Bcl-xL (yellow/slate):
BidBH3:Bax (magenta/green)
Peptide h4
Bcl-xL A93
    Bax I66
60°
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N-terminus
Cavity
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Bax L63
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A
Figure 4. Comparison with Structures of Bcl-xL:BH3 Complexes
(A) Cavity (orange, 140 A˚3) in the hydrophobic core of BidBH3:Bax complex between a2, a5, and a8. The cavity is adjacent to Bax a2 residues L63 and I66 (side
chains shown in gray). The largest comparable cavity in BimBH3:Bcl-xL is 20 A˚
3.
(B) Overlay of BidBH3:Bax with BimBH3:Bcl-xL and zoom showing relative displacement of the Bax a2 and the contacts between hydrophobic residues on the
BH3 domains of protein (h3 residues Bcl-xL A93/Bax I66) and peptide (h4 residues Bid M97/Bim F159).
See also Figure S4.(Figures 3B–3D and S3A–S3D). Bid mini (truncated at D98) re-
tained activity, suggesting that residues C-terminal to h4 are
not essential. Notably, Bid I82A/I83A lost activity in all assays,
establishing the importance of these h0 residues (Figure 2B)
for Bid’s activating function. The h1 position is also important
because a single-residue replacement to Noxa at h1 (C25I)
rendered it both able to activate Bax in biochemical assays
and to trigger Bax-mediated cytochrome c release from mouse
liver mitochondria (Figures 3B–3D). This result was not due to
increased binding of Noxa C25I to prosurvival proteins (Table
S2). Similarly, four replacements in Bad at the h0, h1, and to
the unusual Ser after h3 made Bad mut4 (A106I/A107I/Y110I/
S118G) an activator (Figure 3). The apparent anomaly that
some activator sequences (Bim and Noxa C25I) have glutamic
acid in h0 rather than isoleucine was resolved when we noted
that the BidBH3:BaxDC21 structure would allow a glutamic
acid in h0 to form a salt bridge with Bax Arg94 (Figure 2B).
Indeed, Bim and Noxa mutants (Bim P144A/E145A, Noxa h0
A/C25I) confirmed that either glutamate or isoleucine in h0
promotes activator function (Figure 3B).
To confirm that binding of the peptides into the Bax groove
was critical, we mutated the conserved arginine (R109) in the
Bax groove to aspartate to preclude its association with the
invariant aspartate (D68) in the Bax BH3 (Figures 3A and S2B).
As expected, Bax R109D was not dimerized by the Bax wild-
type BH3 peptide but was dimerized by the charge-swapmutant
BaxBH3 peptide D68R (Figure 3E). Hence, the phenomena
monitored here require peptide binding in the groove.
Structural Consequences of Activator Peptide
Binding to Bax
Although the BidBH3:BaxDC21 complex resembles prosurvival
proteins with bound BH3 peptides, notable differences explain
how activator BH3-only proteins trigger structural transitions inBax. A striking anomaly of the BidBH3:BaxDC21 structure is
the presence of a cavity (Dundas et al., 2006) between Bax
helices a2, a5, and a8 (Figure 4A), also seen in the BaxBH3:
BaxDC21 complex (Figure S4A). By contrast, the structure of
BaxDC21 without a bound BH3 peptide (see below) and those
of prosurvival family members bound to BH3 peptides contain
no cavity. Cavities destabilize globular proteins (Baase et al.,
2010), in this case promoting extrusion of Bax a2, its BH3
domain. Release of this domain is a critical step in Bax (and
Bak) dimerization (see Discussion).
Structural features associated with the cavity are revealed in
an overlay of the structures of BidBH3:BaxDC21 with BimBH3:
Bcl-xL (Lee et al., 2009; Liu et al., 2003). The C-terminal half of
Bax a2 is more removed from the Bid peptide than their counter-
parts in BimBH3:Bcl-xL (Figure 4B). Furthermore, the Bid peptide
is slightly displaced toward its C-terminal end compared to
Bim bound to Bcl-xL. Similar features are seen in the BaxBH3:
BaxDC21 structure (Figure S4B). Sequence differences between
Bcl-xL and Bax help to explain these discrepancies (Figure S4C).
First, Bax has two fewer residues than Bcl-xL in the a2/a3 corner,
and this affects the conformation of adjacent residues on a2 and
a3. Second, the third signature hydrophobic residue (h3) in the
BH3 motif of Bax (I66) and Bak (I81) is invariably a large hydro-
phobic residue, usually isoleucine, whereas four of the six human
prosurvival proteins have a small residue, alanine, in this posi-
tion. Thus, in the BidBH3:BaxDC21 structure, Bid h4 residue
M97 contacts Bax I66 in a2, whereas in the BimBH3:Bcl-xL
structure Bim F159 (h4) abuts A93 (h3) in Bcl-xL a2 (Figure 4B).
Accordingly, Bim F159A and Bid M97A peptides have reduced
capacity to dimerize BaxDC21 and have even less capacity
with BaxDC21 I66A (Figure S4D).
The other marked effect on BaxDC21 of the peptide binding
was its transformation from monomer to dimer, which is
addressed next.Cell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc. 523
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Figure 5. Bax Core and Latch Domains
Separate during Apoptosis
(A)Core/latchdomain-swappeddimer ofBaxDC21
(chainA rainbowas in Figure 2A; chainB, gray). The
disordered loop between a1 and a2 introduces an
uncertainty in assigning a1 to chain A or B.
(B) A putative intermediate in transition from
monomeric BaxDC21 to the structure in (A),
exposing the 49F9 epitope (magenta). V121 and
I136, where cysteine substitutions were made to
tether a5 to a6, are labeled. Some unfolding of the
latch (and to a lesser extent the core) is expected
during the transition.
(C) The a5–a6 tether forms on mitochondria only
before activation with tBid. Membrane fractions
were treated with or without tBid prior to induction
of disulfide-linkage with copper(II)(1,10-phenan-
throline) (CuPhe).
(D) The a5–a6 tether prevents Bax function.
Membrane fractions were treated with CuPhe
prior to tBid-induced cytochrome c release. SN,
supernatant fraction.
(E) The a4–a5 tether persists after activation
with tBid. Membrane fractions were treated as
in (C).
(F) The a4–a5 tether does not affect function.
Membrane fractions were treated as in (D). Data in
(C)–(F) are representative of three experiments
with mitochondria from Bax/ Bak/ cells stably
expressing the indicated Bax variants.
(G and H) (G) BaxDC21 with the mutation V121C/
I136C still binds BidBH3 peptide, both before and
after oxidation (IC50 250 ± 32 nM and 159 ±
45 nM, respectively; SD, n = 3), and in (H), the
reduced form can be dimerized by CHAPS plus
BimBH3, but the oxidized form cannot.
See also Figure S5.The Domain-Swapped Dimer Suggests that Bax
Separates into Two Domains
Untreated BaxDC21 is a monomer (Figure 1), as NMR con-
firms (Figure S5A), but BaxDC21 activated in various ways
routinely yielded crystal structures of domain-swapped dimers.524 Cell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc.Thus, the protein dimerized by octylmal-
toside or by BimBH3 plus CHAPS but
without excess peptide during crystal-
lization (Apo dimers in Table S1) yielded
indistinguishable structures, lacking a
bound peptide (Figure 5A). All revealed
a BaxDC21 domain-swapped dimer in
which two Bax polypeptides had swap-
ped helices a6, a7, and a8 (hereafter
a6–a8 or the ‘‘latch domain’’). Thus,
each globular unit comprises a1–a5
(the ‘‘core domain’’) from one Bax poly-
peptide plus a6–a8 from the other,
bridged by two antiparallel extended
a5–a6 helices (Figure 5A). We term this
domain-swapped dimer the ‘‘core/latch’’
dimer. Note that the disorder in the
loop connecting a1 to a2 leaves openthe possibility that a1 is part of the latch rather than the core
domain.
We suggest that the unfolding event that dissociates the core
and latch domains (Figure 5B) is on the pathway to Bax oligomer-
ization, but the core/latch dimer itself is off pathway because its
structure (Figures 2A and 5A) is inconsistent with all data on
interfaces in Bax (or Bak) oligomers formed during apoptosis
(Bleicken et al., 2010; Dewson et al., 2008, 2012; Zhang et al.,
2010). In our experiments, the absence of orienting membranes
and the increased stability of domain-swapped structures over
their monomeric counterparts (Bennett and Eisenberg, 2004)
most likely promoted formation of the off-pathway core/latch
dimer.
We propose that, when an activator such as tBid or Bim
engages Bax, for example, when anchored in the MOM via a9,
it triggers release of the core from the latch, and this suffices
to expose the N-terminal epitope (Figures 1D and 5B). In our
biochemical experiments, this exposure is transient due to the
formation of the core/latch dimer. At the MOM, the membrane
environment, together with the activator BH3 domain (Lovell
et al., 2008), helps to ‘‘unlatch’’ the core domain and direct the
oligomerization along a path that precludes the core/latch dimer
(see Discussion).
Tethering Helix a5 to a6 Inactivates Bax
Because the proposed ‘‘unlatching’’ model suggests that Bax
activation disengages a5 from a6 (Figure 5B), tethering the two
helices together by a disulfide bond might inactivate Bax. To
test this hypothesis, we engineered a cysteine into a5 (V121C)
and a6 (I136C) and introduced these single mutations and the
double mutation V121C/I136C within full-length Bax (C62S,
C126S) also bearing the mutation S184L in a9 to render Bax
MOM-associated (Fletcher et al., 2008; Nechushtan et al.,
1999). All mutants retained apoptotic function when stably ex-
pressed in Bax/Bak/ fibroblasts (Figures S5F and S5G),
and the oxidized, recombinant V121C/I136C mutant retains
structure (Figure S5H) and capacity to bind BH3 peptides,
though not to dimerize (Figures 5G and 5H). Consistent with
dissociation of a5 and a6 upon Bax activation, disulfide linkage
of the double cysteine mutant, as indicated by aberrant migra-
tion on nonreducing SDS-PAGE (Ruiz et al., 2010), was lost after
tBid treatment (Figure 5C). A disulfide tether between a5 and a6
blocked tBid-induced cytochrome c release, whereas oxidation
of the single cysteine variants had no effect (Figure 5D). Bax with
cysteines introduced instead into both a4 and a5 remained func-
tional even when disulfide tethered (Figures 5E, 5F, S5F, and
S5G). These results argue that a5 and a6 must dissociate during
Bax activation and that V121 and I136 are not proximal after acti-
vation (Figure 5B).
Structure of a Bax BH3-in-Groove Homodimer
To study the structural properties of the unlatched core
domain while precluding formation of the off-pathway core/
latch dimer, we made Bax constructs lacking the latch
domain. Because the isolated core domain (a1–a5) would
expose hydrophobic surfaces that might promote aggregation,
we fused it to green fluorescent protein (GFP) to facilitate crys-
tallization (Suzuki et al., 2010). We also made a GFP-Bax(a2–
a5) fusion because a2–a5 suffices for oligomerization (George
et al., 2007).
The GFP was dimeric when expressed alone, but both GFP-
Bax fusions behaved mainly as a tetramer on gel filtration (Fig-
ure S6F), suggesting that the Bax core domain, with or withouta1, had dimerized and linked GFP dimers. The purified GFP-
Bax(a2–a5) tetramer was crystallized, and its structure was
determined by molecular replacement, phasing the Bax(a2–a5)
from the GFP (Table S1 and Figures S6A and S6B). Although
the diffraction data extend to 3 A˚ resolution, that of the
Bax(a2–a5) domain is significantly lower (estimated 4 A˚). In
the crystal, two dimers of Bax(a2–a5) have indeed linked two
GFP dimers into tetramers (Figures S6C and S6D). Because
the two Bax polypeptides within each dimeric unit are fused
to different GFP dimers, GFP dimerization did not cause
Bax(a2–a5) dimerization.
Bax(a2–a5) formed a symmetric dimer in which helix a2 (the
BH3 domain) of each monomer engages helices a3–a5 of the
other monomer (Figure 6A). One half of the dimer, i.e., a2 of
one monomer and a3–a5 of the other, closely resembles the
complex between the BaxBH3 peptide and BaxDC21 (Fig-
ure 6B). Thus, this dimer is held together by contacts made in
both of its BH3-in-groove interfaces. The two antiparallel a2
helices (BH3 domains) are close together, their E69 residues
being only 9.3 A˚ apart. Accordingly, when stably expressed in
Bak/Bax/MEF, full-length mitochondrial Bax E69C residues
exposed to an apoptotic stimulus (tBid) could be crosslinked
with the 8 A˚ linker BMOE, whereas residues farther apart
(R65C) could not (Figure 6C).
This homodimer has a layer of two a2 and a3 helices stacked
above a layer of two a4 and a5 helices. The angle between
helices a2 and a3 within a Bax polypeptide is 120 versus
90 in the BaxBH3:Bax complex, juxtaposing the two hydro-
phobic a5 helices. Whereas in monomeric BaxDC21 the latch
domain buries the hydrophobic surfaces of a4 and a5, here
they form a continuous planar surface with their counterparts
on the partner molecule (Figure 6A). Six of the eight aromatic
amino acids in Bax(a2–a5)—F92, F93, F100, F105, W107,
and F114—and their symmetry equivalents in the dimer localize
to this lipophilic surface, which may represent a region of
membrane contact (see below).
These results strongly support the concept that the BH3-in-
groove symmetric dimer is the fundamental unit of the Bax
oligomer.
DISCUSSION
Our studies with BaxDC21 reveal structural transitions that drive
inactive, monomeric Bax on the path to an apoptotic oligomer.
With this construct, we cannot directly address the earliest Bax
transitions, which presumably occur on cytosolic Bax, where
a9 occupies the a2–a5 groove (Gavathiotis et al., 2008; Kim
et al., 2009). Although the core/latch dimer we describe is
unlikely itself to figure in oligomerization, it has revealed an
unsuspected Bax transition: its N-terminal core (a1–a5) disen-
gages from the C-terminal latch (a6–a8). This transition (Fig-
ure 5B) appears to be critical for Bax function because tethering
a5 to a6 ablated cytochrome c release by full-length Bax (Fig-
ure 5C). That result might seem incompatible with a model in
which a5a6 hairpins enter the MOM during its permeabilization
(Annis et al., 2005). Our model only requires that these helices
separate in an essential early step. We have not addressed
whether or not a5 and a6 might reform a hairpin during MOMCell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc. 525
Figure 6. The BH3-in-Groove Symmetric
Dimer Formed by Bax(a2–a5)
(A) Each polypeptide is colored rainbow as in
Figure 5B, cyan at the N terminus of a2 through
yellow at the C terminus of a5. The helices of one
polypeptide are labeled. E69 and R65 are indi-
cated in the left view, and aromatic residues
concentrated on one surface are indicated in the
right view, the putative ‘‘membrane view.’’
(B) Overlay of one half of the above dimer (a2 from
one polypeptide, a3–5 from the other) with the
BaxBH3:BaxDC21 complex (see Figure S2B).
(C) Bax E69C can be crosslinked on mitochondria.
Membrane fractions from Bax/ Bak/ cells
stably expressing the indicated Bax S184L vari-
ants were treated with or without tBid prior to
crosslinking with BMOE. Note that R65C one turn
away on helix a2 cannot crosslink.
See also Figure S6.permeabilization. If they do, the disulfide-linkage data argue that
they assume a different orientation.
Activator BH3 Binding Initiates Bax Conformational
Changes
We propose that the globular structure of BaxDC21 complexed
with the Bid or Bax BH3 peptide (i.e., the globule above the
dotted line in Figure 2A) represents the complex that monomeric
Bax forms with a direct activator on the MOM. Notably, cavities
appear in the Bax:BH3 peptide structures at the interface
between the core and latch domains (Figures 4A and S4A). No
such cavities appear in the equivalent Bax structures without
the bound peptide, nor do they appear in the complexes of
BH3 peptides with prosurvival Bcl-2 relatives. Because such
cavities are destabilizing (Baase et al., 2010), these findings
strongly suggest that a bound activator BH3 peptide induces
a metastable Bax structure that facilitates release of the core
and its a2 segment. These structures thus resolve the central526 Cell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc.mystery of how the Bax BH3 domain is
liberated to trigger Bax oligomerization.
Whereas prosurvival family members
remain intact on binding a BH3 peptide,
Bax instead releases its core domain
and its own BH3 domain (a2). The freed
Bax a2 can then compete with an acti-
vator BH3 domain, e.g., that of Bid, for
binding another multidomain family
member; its sequestration by a prosur-
vival relative can preserve mitochondrial
integrity, whereas its engagement of
another Bax molecule sets it on the path
to MOM permeabilization.
Exposure of an N-terminal epitope,
a hallmark of Bax in dying cells, is
thought to require release of a1, but
core/latch dissociation offers an alterna-
tive mechanism. We suggest that the
unlatched form occurs in activated full-length Bax monomers associated with membranes or lipo-
somes. Pertinently, excision of its N-terminal 19 or 20 residues
targets Bax to the MOM (Cartron et al., 2002; Goping et al.,
1998). Because I19, at the a1 N terminus, packs against
L149 and I152 in a7, its absence is likely to facilitate core/latch
separation. Thus, N-terminal mutations promoting Bax activa-
tion may act by decreasing Bax stability, allowing core/latch
disengagement. Certain C-terminal deletions may also promote
their dissociation. We find that Bax lacking its C-terminal 25 or
28 residues behaves like BaxDC21 in the presence of deter-
gents and BH3 peptides but that BaxDC29, which also re-
moves Y164, does not express as a monomeric protein (data
not shown). Pertinently, the constitutively active isoform Baxb
has a distinct sequence after S163 (Fu et al., 2009), and
BaxDC35 aggregates and exposes the N-terminal 6A7 epitope
(Liu et al., 2003). These data suggest that Y164 (Figure 2B)
makes critical interactions at the core/latch interface to stabi-
lize the inactive form of Bax.
Activator BH3 Sequences and Their Binding Site
We identified sequences distinguishing activator and sensitizer
BH3 domains and designed mutants that converted sensitizers
into activators (Figure 3). We show that a critical element lies
N-terminal to the core BH3 domain in a position we term h0,
where either an isoleucine or a glutamate favors activator
function on Bax. An isoleucine at h1 is also important, as is the
almost invariant glycine between h3 and h4. These findings
suggest ways to design BH3 sequences that retain interactions
with prosurvival proteins, but not with Bax.
Could peptide binding to an alternate ‘‘rear site’’ (Gavathiotis
et al., 2008) have triggered the dimerization we observed,
despite Bid and Bax peptides appearing in the groove? That
appears untenable because Bax groove mutant R109D was
not dimerized by the wild-type BaxBH3 peptide (Figure 3E).
Furthermore, the critical h0 residues of Bid and Bim would lie
well outside the proposed rear site, and the important h1 resi-
dues would lie at its periphery (Figure S3E). Our studies,
however, do not address whether some such alternative site
contributes to earlier activation steps, such as release of a9
from the groove. Hence, BH3 interactions with two different sites
on Bax may play sequential roles in activation, as some
biochemical evidence suggests (Kim et al., 2009).
The BH3-in-Groove Dimer as the Central
Oligomerization Unit
We suggest that the Bax(a2–a5) dimer (Figure 6A) nucleates Bax
oligomerization. This dimer is essentially a head-to-head com-
posite of two BaxBH3:BaxDC21 peptide complexes, stripped
of thea1helix and the latchdomain (Figure 6B). That sucha struc-
ture forms in dying cells is supported by crosslinking studies on
Bax (and Bak) dimers in apoptotic cells (Dewson et al., 2008,
2012), EPR measurements on activated Bax in liposomes
(Bleicken et al., 2010), photocrosslinking studies (Zhang et al.,
2010), and evidence that Bax M74 mutants (at the h5 position in
the Bax BH3), which retain capacity to homo-oligomerize (Cza-
botar et al., 2011), lie outside the dimerization interface (Fig-
ure S6E). These findings argue against the proposal that the
central unit of polymerization is a monomer engaging another
monomer in a head-to-tail (‘‘daisy-chain’’) manner (Bogner
et al., 2010; Pang et al., 2012). Which of the surfaces exposed
on the Bax(a2–a5) dimer promote its association into larger olig-
omers is unknown, although crosslinking studies suggest that
multimerization ofBakorBaxdimers onmitochondria brings their
a6 helices into proximity (Dewson et al., 2009; Zhang et al., 2010).
How Bax oligomerization perforates the MOM remains a
mystery (Westphal et al., 2011). Known pore-forming proteins
that assemble from a soluble monomer create proteinaceous
pores with circular n-fold symmetry and pores of a unique or
narrowly defined size (Mueller et al., 2009; Tilley and Saibil,
2006). Curiously, the pore-forming domains of bacterial colicins,
which resemble the Bcl-2 family fold (Muchmore et al., 1996),
seem to function as monomers creating small pores for ions,
not macromolecules (Parker and Feil, 2005). No precedent
currently exists for assembling a pore-forming oligomer from
membrane-anchored dimers. Several reports suggest instead
that the Bax pore is lipidic (Epand et al., 2003; Qian et al.,
2008; Terrones et al., 2004).Significantly, the BH3-in-groove homodimer (Figure 6A) has
a high concentration of aromatic residues (ten phenylalanines
and two tryptophans) on the planar surface comprising the
exposed faces of the a4 and a5 helices from each monomer.
This finding tempts speculation that this surface lies along the
MOM; insertion of these residues between the head groups of
the MOM lipids would promote positive curvature and tension
in the outer leaflet of that membrane (Fuhrmans and Marrink,
2012), steps thought to promote the opening of a lipidic pore.
The latch domain is also amphipathic and might associate simi-
larly with the MOM surface without necessarily actively contrib-
uting to pore formation.
Conclusions
Our findings, summarized in Figure 7A, thus support a model
(Figure 7B) for activation of MOM-anchored Bax in which an acti-
vator BH3-only protein inserts its BH3 domain into the canonical
groove of Bax, initiating release of the core domain (a1–a5) from
the latch domain (a6–a8) and dislodgement of Bax a2 (its BH3
domain). The freed Bax BH3 domain can then compete with acti-
vator BH3-only proteins for the groove of another Bax molecule
due to the increased stability of the BH3-in-groove symmetric
dimer. These steps further clarify the catalytic role of activator
BH3 domains in Bax oligomerization (Billen et al., 2008; Bleicken
et al., 2010). The symmetric dimer can then nucleate oligomeri-
zation of the Bax core domain (Dewson et al., 2012; George
et al., 2007) and hence provoke MOM permeabilization. Similar
interactions between BH3 activators and the canonical groove
of the MOM-anchored Bak may well initiate its oligomerization
(Dai et al., 2011).
The structures of the prosurvival Bcl-2 proteins have guided
the development of the promising anticancer ‘‘BH3 mimetics’’
(Lessene et al., 2008). Our results suggest that the groove of
Bax andBak could also be a valid therapeutic target and suggest
a rationale for discovering both agonists and antagonists that
respectively promote or hinder release of their core domain
and/or helix a2 (their BH3 domain). Targeting these critical
apoptotic effectors might improve treatment of diseases with
attenuated apoptosis (e.g., cancer and autoimmune disease)
or those with excessive cell death (degenerative disorders).
EXPERIMENTAL PROCEDURES
Procedures for assigning BaxDC21 backbone chemical shifts, epitope
mapping of antibody 49F9, immunoprecipitation of mitochondrial Bax, cyto-
chrome c release from mouse liver mitochondria, release of dextran from
liposomes, measuring peptide affinity for Bcl-xL, and binding of peptides to
Bax are in Extended Experimental Procedures.
Peptides and Recombinant Proteins
Peptides were purchased fromMimotopes Australia. Recombinant Bax(DC21;
C62S, C126S), full-length Bax, and variants thereof were produced by
a protocol modified from that described (Suzuki et al., 2000). Bax cloned
into pTYB1 was expressed in E. coli BL21(DE3) cells. Cells were lysed in
TBS (20 mM Tris [pH 8.0], 150 mM NaCl), and proteins were purified by chitin
affinity chromatography followed by gel filtration (Superdex75) in TBS.
Dimer Preparation, Crystallization, Data Collection, and Processing
Our first solved structure was the Bax dimer induced by octylmaltoside (OM).
To produce it, protein at 7 mg/ml was treated with 1%OM in TBS for 10 min atCell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc. 527
Figure 7. Models Demonstrating Our Conclusions Regarding BaxDC21 Activation and Bax(a2–a5) Dimerization and Their Implications for
Bax Anchored to the MOM
(A) (i) BaxDC21 is monomeric in the absence of detergents or CHAPS plus BH3 peptides. (ii) Binding of an activator BH3 peptide into the Bax canonical groove
unlatches the core domain (a1–a5). (iii) In the absence of an orienting membrane tether, two such unlatched molecules combine (‘‘head to tail’’) to form the core/
latch dimer. Note the change in orientation of the core in these figures once the latch is released (i to ii). The core alone instead forms the on-pathway BH3-in-
groove symmetric dimer.
(B) With MOM-anchored native Bax, we propose that activator BH3 domains bind into the groove and unlatch the structure as in (A), releasing the Bax BH3
domain and allowing it to compete for the groove of neighboring Bax molecules on the MOM. The final complex, the BH3-in-groove symmetric Bax dimer, is
favored due to the stability afforded by dimerization. In that dimer, the positions of the latch domain and the membrane-anchoring a9 are unknown. The dimer’s
lipophilic a4–a5 surface may engage the MOM and promote its permeabilization.room temperature (RT), dialysed for 48 hr against TBS at 4C, and purified
by gel filtration in TBS. Crystals of dimer (5 mg/ml) grew at RT in 1.8 M
NH4SO4, 0.1 M HEPES (pH 6.5), and 10 mM PrCl3. Crystals were frozen
in well solution supplemented with 20% ethylene glycol and X-ray data
collected at the Australian Synchrotron beamline MX2 at 100 K. Data were
processed with HKL2000 (Otwinowski and Minor, 1997), and the structure
was solved by SAD phasing with PHENIX Autosolve (Adams et al., 2010),
which found two Pr sites and built 345 residues. Further rounds of building
in COOT (Emsley and Cowtan, 2004) and refinement in PHENIX yielded the
final model, which was used for molecular replacement in subsequent struc-
ture solutions.
BH3-induced Bax dimers were produced by treating protein at 2 mg/ml with
0.5% CHAPS and a 2-fold molar excess of BH3 peptide in TBS (1 hr, RT). The
dimer fraction was purified on a Superdex75 column in TBS and crystallized
under similar conditions to the OM-induced dimers. Crystals were frozen in
cryo-protectant, data were collected on MX2, data were processed with
XDS (Kabsch, 2010), and the structure was solved by molecular replacement528 Cell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc.with PHASER (McCoy et al., 2007). Further rounds of building in COOT and
refinement in PHENIX resulted in the final model.
Crystals of Bax:BH3 complexes were obtained by supplementing purified
BH3-induced dimers with an excess of the corresponding BH3 peptide.
Crystals grew from well solutions containing sodium malonate or sodium
citrate in various buffers. The Bax:BidBH3 complex crystal grew in 1.4 M
sodium citrate and 0.1 M sodium cacodylate (pH 5.75). Crystals were
frozen in well solution supplemented with 20% ethylene glycol, and data
were collected on MX2. Data processing, structure solution, building, and
refinement were as above. The structures were solved by molecular
replacement, the Bax moiety clearly phasing the peptide (Figure S2A). All
structures were validated using tools in PHENIX and COOT (Emsley and
Cowtan, 2004).
Bax Core Domain Constructs and Crystallography
Sequence encoding a2–a5 of Bax (D53-K128, C62S, C126S) and a1–a5 (P13-
K128, C62S, C126S) were cloned into pET28a-GFP (Suzuki et al., 2010). GFP
for the a2–a5 construct encoded an unintentional mutation (A206N).
Expression and purification were as above except that affinity purification
was via the His Tag, removed by thrombin cleavage before gel filtration.
Crystals grown in 10% PEG3350, 20% MPD, 0.5% CHAPS, and 0.1 M Tris
(pH 8.0) were frozen in well solution, and data were collected on MX2 and pro-
cessed with XDS. The structure was solved searching for GFP with PHASER,
revealing density for helical regions of Bax (Figure S6A). PHASER was then
used to place the relevant regions of the BaxBH3:Bax model followed by
rounds of building in COOT and refinement in PHENIX with 4-fold NCS
restraints.
Blue Native PAGE
5 mg of Bax dimers induced by BH3 peptides (in presence of 5 mM DTT) or
OM as described above were analyzed using Invitrogen blue native (BN)
PAGE gels.
Cysteine-Linking andCytochrome cRelease fromMouse Embryonic
Fibroblasts
Cysteine mutants of Bax S184L were stably expressed in Bax/ Bak/
mouse embryonic fibroblasts (MEF), and their function was assessed by
analyzing the percentage of propidium iodide-positive cells after etoposide
exposure (10 mM, 24 hr). For induction of disulfide linkage, heavy membrane
fractions enriched for mitochondria were treated with the oxidant cop-
per(II)(1,10-phenanthroline) (CuPhe 1 mM, 15 min, 4C). Cytochrome c release
assays of oxidized Bax S184L in response to tBid (100 nM, 30 min, 30C) were
performed as described for Bak (Dewson et al., 2008). Supernatant and pellet
fractions were separated and analyzed for cytochrome c by immunoblotting.
Cysteine crosslinking with bismaleimidoethane (BMOE, Pierce) was per-
formed as described (Dewson et al., 2008).
Detection of N-Terminal Conformational Changes
1 mg of 49F9, which recognizesBax only after an apoptotic stimulus (Figure S1),
was added to 0.5 mg of BaxDC21 (2.5 mM) with or without 1% OM (1 hr, RT).
Samples were incubated with Protein-G sepharose beads (1 hr, RT) in TBS
with 1% CHAPS to minimize nonspecific binding. As a control, Bax was
incubated with beads in the absence of 49F9. Samples were washed
four times (TBS with 0.1% CHAPS) before resuspension in loading buffer;
100 ng of IP samples or 10 ng of pre-IP samples were run on SDS PAGE
and blotted for Bax.
ACCESSION NUMBERS
The PDB accession numbers for the structures reported in this paper are
4BD2, 4BD6, 4BD7, 4BD8, and 4BDU.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2012.12.031.
ACKNOWLEDGMENTS
We thank Ahmed Wardak, Geoff Thompson, Hong Yang, Eden Whitlock, and
Leonie Gibson for technical support; Jacqui Gulbis for comments on the
manuscript; and beamline staff at the Australian Synchrotron, where diffraction
data were collected. We thank Richard Youle for the full-length Bax construct,
Motoshi Suzuki and Nico Tjandra for NMR chemical shift data, and Masato
Kawasaki for the pET28a-GFP vector. Crystallization experiments were per-
formed at the Bio21 C3 Collaborative Crystallization Centre. P.E.C. acknowl-
edges an ARC Future Fellowship, and D.W. acknowledges a DFG (Germany)
Postdoctoral Fellowship. Our work is supported by NHMRC (Australia), ARC
(Australia), the Australian Cancer Research Foundation, the Cancer Council
of Victoria, the Leukemia and Lymphoma Society (US), the Victorian State
Government Operational Infrastructure Support, and the Australian Govern-
ment NHMRC IRIISS.Received: July 4, 2012
Revised: October 11, 2012
Accepted: December 10, 2012
Published: January 31, 2013REFERENCES
Adams, P.D., Afonine, P.V., Bunko´czi, G., Chen, V.B., Davis, I.W., Echols, N.,
Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010).
PHENIX: a comprehensive Python-based system for macromolecular struc-
ture solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221.
Annis, M.G., Soucie, E.L., Dlugosz, P.J., Cruz-Aguado, J.A., Penn, L.Z., Leber,
B., and Andrews, D.W. (2005). Bax forms multispanning monomers that
oligomerize to permeabilize membranes during apoptosis. EMBO J. 24,
2096–2103.
Baase, W.A., Liu, L., Tronrud, D.E., and Matthews, B.W. (2010). Lessons from
the lysozyme of phage T4. Protein Sci. 19, 631–641.
Bennett, M.J., and Eisenberg, D. (2004). The evolving role of 3D domain
swapping in proteins. Structure 12, 1339–1341.
Billen, L.P., Kokoski, C.L., Lovell, J.F., Leber, B., and Andrews, D.W. (2008).
Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS
Biol. 6, e147.
Bleicken, S., Classen, M., Padmavathi, P.V., Ishikawa, T., Zeth, K., Steinhoff,
H.J., and Bordignon, E. (2010). Molecular details of Bax activation, oligomer-
ization, and membrane insertion. J. Biol. Chem. 285, 6636–6647.
Bogner, C., Leber, B., and Andrews, D.W. (2010). Apoptosis: embedded in
membranes. Curr. Opin. Cell Biol. 22, 845–851.
Cartron, P.F., Oliver, L., Martin, S., Moreau, C., LeCabellec, M.T., Jezequel, P.,
Meflah, K., and Vallette, F.M. (2002). The expression of a new variant of the
pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival
of glioblastoma multiforme patients. Hum. Mol. Genet. 11, 675–687.
Certo, M., Del Gaizo Moore, V., Nishino, M., Wei, G., Korsmeyer, S.,
Armstrong, S.A., and Letai, A. (2006). Mitochondria primed by death signals
determine cellular addiction to antiapoptotic BCL-2 family members. Cancer
Cell 9, 351–365.
Czabotar, P.E., Lee, E.F., Thompson, G.V., Wardak, A.Z., Fairlie, W.D., and
Colman, P.M. (2011). Mutation to Bax beyond the BH3 domain disrupts
interactions with pro-survival proteins and promotes apoptosis. J. Biol.
Chem. 286, 7123–7131.
Dai, H., Smith, A., Meng, X.W., Schneider, P.A., Pang, Y.P., and Kaufmann,
S.H. (2011). Transient binding of an activator BH3 domain to the Bak
BH3-binding groove initiates Bak oligomerization. J. Cell Biol. 194, 39–48.
Dewson, G., Kratina, T., Sim, H.W., Puthalakath, H., Adams, J.M., Colman,
P.M., and Kluck, R.M. (2008). To trigger apoptosis, Bak exposes its BH3
domain and homodimerizes via BH3:groove interactions. Mol. Cell 30,
369–380.
Dewson, G., Kratina, T., Czabotar, P., Day, C.L., Adams, J.M., and Kluck, R.M.
(2009). Bak activation for apoptosis involves oligomerization of dimers via
their alpha6 helices. Mol. Cell 36, 696–703.
Dewson, G., Ma, S., Frederick, P., Hockings, C., Tan, I., Kratina, T., and Kluck,
R.M. (2012). Bax dimerizes via a symmetric BH3:groove interface during
apoptosis. Cell Death Differ. 19, 661–670.
Dundas, J., Ouyang, Z., Tseng, J., Binkowski, A., Turpaz, Y., and Liang, J.
(2006). CASTp: computed atlas of surface topography of proteins with
structural and topographical mapping of functionally annotated residues.
Nucleic Acids Res. 34(Web Server issue), W116–W118.
Edlich, F., Banerjee, S., Suzuki, M., Cleland, M.M., Arnoult, D., Wang, C.,
Neutzner, A., Tjandra, N., and Youle, R.J. (2011). Bcl-x(L) retrotranslocates
Bax from the mitochondria into the cytosol. Cell 145, 104–116.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular
graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132.Cell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc. 529
Epand, R.F., Martinou, J.C., Montessuit, S., and Epand, R.M. (2003). Transbi-
layer lipid diffusion promoted by Bax: implications for apoptosis. Biochemistry
42, 14576–14582.
Fletcher, J.I., Meusburger, S., Hawkins, C.J., Riglar, D.T., Lee, E.F., Fairlie,
W.D., Huang, D.C., and Adams, J.M. (2008). Apoptosis is triggered when
prosurvival Bcl-2 proteins cannot restrain Bax. Proc. Natl. Acad. Sci. USA
105, 18081–18087.
Fu, N.Y., Sukumaran, S.K., Kerk, S.Y., and Yu, V.C. (2009). Baxbeta: a consti-
tutively active human Bax isoform that is under tight regulatory control by the
proteasomal degradation mechanism. Mol. Cell 33, 15–29.
Fuhrmans, M., and Marrink, S.J. (2012). Molecular view of the role of fusion
peptides in promoting positive membrane curvature. J. Am. Chem. Soc.
134, 1543–1552.
Gavathiotis, E., Suzuki, M., Davis, M.L., Pitter, K., Bird, G.H., Katz, S.G., Tu,
H.C., Kim, H., Cheng, E.H., Tjandra, N., and Walensky, L.D. (2008). BAX acti-
vation is initiated at a novel interaction site. Nature 455, 1076–1081.
Gavathiotis, E., Reyna, D.E., Davis, M.L., Bird, G.H., and Walensky, L.D.
(2010). BH3-triggered structural reorganization drives the activation of proap-
optotic BAX. Mol. Cell 40, 481–492.
George, N.M., Evans, J.J., and Luo, X. (2007). A three-helix homo-oligomeriza-
tion domain containing BH3 and BH1 is responsible for the apoptotic activity of
Bax. Genes Dev. 21, 1937–1948.
Goping, I.S., Gross, A., Lavoie, J.N., Nguyen, M., Jemmerson, R., Roth, K.,
Korsmeyer, S.J., and Shore, G.C. (1998). Regulated targeting of BAX to
mitochondria. J. Cell Biol. 143, 207–215.
Hsu, Y.T., and Youle, R.J. (1997). Nonionic detergents induce dimerization
among members of the Bcl-2 family. J. Biol. Chem. 272, 13829–13834.
Hsu, Y.T., and Youle, R.J. (1998). Bax inmurine thymus is a soluble monomeric
protein that displays differential detergent-induced conformations. J. Biol.
Chem. 273, 10777–10783.
Hsu, Y.T., Wolter, K.G., and Youle, R.J. (1997). Cytosol-to-membrane redistri-
bution of Bax and Bcl-X(L) during apoptosis. Proc. Natl. Acad. Sci. USA 94,
3668–3672.
Kabsch, W. (2010). Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132.
Kim, H., Rafiuddin-Shah,M., Tu, H.C., Jeffers, J.R., Zambetti, G.P., Hsieh, J.J.,
and Cheng, E.H. (2006). Hierarchical regulation of mitochondrion-dependent
apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8, 1348–1358.
Kim, H., Tu, H.C., Ren, D., Takeuchi, O., Jeffers, J.R., Zambetti, G.P., Hsieh,
J.J., and Cheng, E.H. (2009). Stepwise activation of BAX and BAK by tBID,
BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 36, 487–499.
Kuwana, T., Mackey, M.R., Perkins, G., Ellisman, M.H., Latterich, M.,
Schneiter, R., Green, D.R., and Newmeyer, D.D. (2002). Bid, Bax, and lipids
cooperate to form supramolecular openings in the outer mitochondrial
membrane. Cell 111, 331–342.
Kuwana, T., Bouchier-Hayes, L., Chipuk, J.E., Bonzon, C., Sullivan, B.A.,
Green, D.R., and Newmeyer, D.D. (2005). BH3 domains of BH3-only proteins
differentially regulate Bax-mediated mitochondrial membrane permeabiliza-
tion both directly and indirectly. Mol. Cell 17, 525–535.
Lee, E.F., Sadowsky, J.D., Smith, B.J., Czabotar, P.E., Peterson-Kaufman,
K.J., Colman, P.M., Gellman, S.H., and Fairlie, W.D. (2009). High-resolution
structural characterization of a helical alpha/beta-peptide foldamer bound
to the anti-apoptotic protein Bcl-xL. Angew. Chem. Int. Ed. Engl. 48,
4318–4322.
Lessene, G., Czabotar, P.E., and Colman, P.M. (2008). BCL-2 family antago-
nists for cancer therapy. Nat. Rev. Drug Discov. 7, 989–1000.
Letai, A. (2009). Puma strikes Bax. J. Cell Biol. 185, 189–191.
Letai, A., Bassik, M.C., Walensky, L.D., Sorcinelli, M.D., Weiler, S., and
Korsmeyer, S.J. (2002). Distinct BH3 domains either sensitize or activate mito-
chondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2,
183–192.530 Cell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc.Liu, X., Dai, S., Zhu, Y., Marrack, P., and Kappler, J.W. (2003). The structure of
a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 19,
341–352.
Llambi, F., Moldoveanu, T., Tait, S.W., Bouchier-Hayes, L., Temirov, J.,
McCormick, L.L., Dillon, C.P., and Green, D.R. (2011). A unified model of
mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell
44, 517–531.
Lovell, J.F., Billen, L.P., Bindner, S., Shamas-Din, A., Fradin, C., Leber, B., and
Andrews, D.W. (2008). Membrane binding by tBid initiates an ordered series
of events culminating in membrane permeabilization by Bax. Cell 135, 1074–
1084.
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C.,
and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Cryst. 40,
658–674.
Muchmore, S.W., Sattler, M., Liang, H., Meadows, R.P., Harlan, J.E., Yoon,
H.S., Nettesheim, D., Chang, B.S., Thompson, C.B., Wong, S.L., et al.
(1996). X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed
cell death. Nature 381, 335–341.
Mueller, M., Grauschopf, U., Maier, T., Glockshuber, R., and Ban, N. (2009).
The structure of a cytolytic a-helical toxin pore reveals its assembly mecha-
nism. Nature 459, 726–730.
Nechushtan, A., Smith, C.L., Hsu, Y.T., and Youle, R.J. (1999). Conformation of
the Bax C-terminus regulates subcellular location and cell death. EMBO J. 18,
2330–2341.
O’Neill, J.W., Manion, M.K., Maguire, B., and Hockenbery, D.M. (2006).
BCL-XL dimerization by three-dimensional domain swapping. J. Mol. Biol.
356, 367–381.
Oh, K.J., Singh, P., Lee, K., Foss, K., Lee, S., Park, M., Lee, S., Aluvila, S., Park,
M., Singh, P., et al. (2010). Conformational changes in BAK, a pore-forming
proapoptotic Bcl-2 family member, upon membrane insertion and direct
evidence for the existence of BH3-BH3 contact interface in BAK homo-
oligomers. J. Biol. Chem. 285, 28924–28937.
Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data
collected in oscillation mode. Macromolecular Crystallography, Pt. Methods
Enzymol. 276, 307–326.
Pang, Y.P., Dai, H., Smith, A., Meng, X.W., Schneider, P.A., and Kaufmann,
S.H. (2012). Bak conformational changes induced by ligand binding: insight
into BH3 domain binding and Bak homo-oligomerization. Sci. Rep. Published
online February 10, 2012. http://dx.doi.org/10.1038/srep00257.
Parker, M.W., and Feil, S.C. (2005). Pore-forming protein toxins: from structure
to function. Prog. Biophys. Mol. Biol. 88, 91–142.
Qian, S., Wang, W., Yang, L., and Huang, H.W. (2008). Structure of transmem-
brane pore induced by Bax-derived peptide: evidence for lipidic pores. Proc.
Natl. Acad. Sci. USA 105, 17379–17383.
Ruiz, N., Chng, S.S., Hiniker, A., Kahne, D., and Silhavy, T.J. (2010). Noncon-
secutive disulfide bond formation in an essential integral outer membrane
protein. Proc. Natl. Acad. Sci. USA 107, 12245–12250.
Sattler, M., Liang, H., Nettesheim, D., Meadows, R.P., Harlan, J.E., Eberstadt,
M., Yoon, H.S., Shuker, S.B., Chang, B.S., Minn, A.J., et al. (1997). Structure of
Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
Science 275, 983–986.
Suzuki, M., Youle, R.J., and Tjandra, N. (2000). Structure of Bax: coregulation
of dimer formation and intracellular localization. Cell 103, 645–654.
Suzuki, N., Hiraki, M., Yamada, Y., Matsugaki, N., Igarashi, N., Kato, R., Dikic,
I., Drew, D., Iwata, S., Wakatsuki, S., and Kawasaki, M. (2010). Crystallization
of small proteins assisted by green fluorescent protein. Acta Crystallogr. D
Biol. Crystallogr. 66, 1059–1066.
Terrones, O., Antonsson, B., Yamaguchi, H., Wang, H.G., Liu, J., Lee, R.M.,
Herrmann, A., and Basan˜ez, G. (2004). Lipidic pore formation by the concerted
action of proapoptotic BAX and tBID. J. Biol. Chem. 279, 30081–30091.
Tilley, S.J., and Saibil, H.R. (2006). The mechanism of pore formation by
bacterial toxins. Curr. Opin. Struct. Biol. 16, 230–236.
Wang, K., Gross, A., Waksman, G., and Korsmeyer, S.J. (1998). Mutagenesis
of the BH3 domain of BAX identifies residues critical for dimerization and
killing. Mol. Cell. Biol. 18, 6083–6089.
Wei, M.C., Zong,W.X., Cheng, E.H., Lindsten, T., Panoutsakopoulou, V., Ross,
A.J., Roth, K.A., MacGregor, G.R., Thompson, C.B., and Korsmeyer, S.J.
(2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial
dysfunction and death. Science 292, 727–730.
Westphal, D., Dewson, G., Czabotar, P.E., and Kluck, R.M. (2011). Molecular
biology of Bax and Bak activation and action. Biochim. Biophys. Acta 1813,
521–531.Wolter, K.G., Hsu, Y.T., Smith, C.L., Nechushtan, A., Xi, X.G., and Youle, R.J.
(1997). Movement of Bax from the cytosol to mitochondria during apoptosis. J.
Cell Biol. 139, 1281–1292.
Youle, R.J., and Strasser, A. (2008). The BCL-2 protein family: opposing
activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47–59.
Zhang, Z., Zhu, W., Lapolla, S.M., Miao, Y., Shao, Y., Falcone, M., Boreham,
D., McFarlane, N., Ding, J., Johnson, A.E., et al. (2010). Bax forms an olig-
omer via separate, yet interdependent, surfaces. J. Biol. Chem. 285,
17614–17627.Cell 152, 519–531, January 31, 2013 ª2013 Elsevier Inc. 531
